Eu-MCV / EuBiologics - LARVOL DELTA

Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old (clinicaltrials.gov) - P1 | N=60 | Completed | Sponsor: EuBiologics Co.,Ltd | Active, not recruiting ➔ Completed | Trial primary completion date: Oct 2023 ➔ May 2023

Trial completion • Trial primary completion date • Infectious Disease • Meningococcal Infections

Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine (EuNmCV-5) in Healthy Adults Aged 19 to 55 Years Old (clinicaltrials.gov) - P1 | N=60 | Active, not recruiting | Sponsor: EuBiologics Co.,Ltd | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Meningococcal Infections

Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old (clinicaltrials.gov) - P1 | N=60 | Recruiting | Sponsor: EuBiologics Co.,Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Meningococcal Infections

Safety and Immunogenicity of Pentavalent Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old (clinicaltrials.gov) - P1 | N=60 | Not yet recruiting | Sponsor: EuBiologics Co.,Ltd

New P1 trial • Infectious Disease • Meningococcal Infections

Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old (clinicaltrials.gov) - P1; N=60; Completed; Sponsor: EuBiologics Co.,Ltd; Active, not recruiting ➔ Completed; Trial completion date: May 2021 ➔ Sep 2021

Clinical • Trial completion • Trial completion date • Infectious Disease • Meningococcal Infections

Safety and Immunogenicity of Meningococcal Conjugate Vaccine in Healthy Adults Aged 19 to 55 Years Old (clinicaltrials.gov) - P1; N=60; Active, not recruiting; Sponsor: EuBiologics Co.,Ltd

Clinical • New P1 trial • Infectious Disease